Esketamine use in real-world clinical practice in patients with treatment-resistant depression.
European psychiatry : the journal of the Association of European Psychiatrists August 26, 2025 Ismael Conejero, Raquel Alvarez García, Alejandro Porras-Segovia et al. 2 citations
In a naturalistic study across four Madrid hospitals, 55% of 65 patients with treatment-resistant depression who received esketamine as an augmentation treatment achieved remission over follow-up. Among those who completed the standard protocol, remission rates rose to 67%, and to 70% for those receiving more than 19 administrations. Remission was associated with completing the standard protocol and with the absence of dissociative symptoms. Receiving more than 19 esketamine administrations increased the odds of remission. Adverse effects did not affect treatment continuation.